A fever call after a bispecific dose
R/R B-cell lymphomatwo days past a bispecific dosefever and new neurologic symptoms at home
Unstable now, or pathway ready?
64%
The patient on the phone
36%
The pathway around them
What matters now
Bispecific toxicity is not consistent across hematologic malignancies. Infection rates with lymphoma bispecifics are less than half those seen with myeloma bispecifics.
R/R B-cell lymphomatwo days past a bispecific dosefever and new neurologic symptoms at home
Unstable now, or pathway ready?
64%
The patient on the phone
36%
The pathway around them
64R/R DLBCL, outpatient bispecificresidual cytopeniasfever and mild confusion on day two
Our capacity, or their condition?
25%
The practice's capacity
75%
The patient's current state
R/R follicular lymphoma, several prior linesoptions differ in benefit, toxicity and daily burden
Start with values, or with constraints?
57%
Values and understanding
43%
Disease and logistics
R/R DLBCL starting step-up dosingsafety rests on site of care, monitoring and handoffs
A standing protocol, or local judgment?
65%
A standing protocol
35%
Judgment and local capacity
73R/R follicular lymphomaseveral comorbidities, ninety-minute drive to the center
Their reserve, or your escalation plan?
65%
Facts about the patient
36%
The escalation plan
What matters now
Bispecific toxicity is not consistent across hematologic malignancies. Infection rates with lymphoma bispecifics are less than half those seen with myeloma bispecifics.
5 Real World Scenarios
R/R B-cell lymphomatwo days past a bispecific dosefever and new neurologic symptoms at home
Unstable now, or pathway ready?
Where does the evidence land?
64%
The patient on the phone
36%
The pathway around them
64R/R DLBCL, outpatient bispecificresidual cytopeniasfever and mild confusion on day two
Our capacity, or their condition?
Where does the evidence land?
25%
The practice's capacity
75%
The patient's current state
R/R follicular lymphoma, several prior linesoptions differ in benefit, toxicity and daily burden
Start with values, or with constraints?
Where does the evidence land?
57%
Values and understanding
43%
Disease and logistics
R/R DLBCL starting step-up dosingsafety rests on site of care, monitoring and handoffs
A standing protocol, or local judgment?
Where does the evidence land?
65%
A standing protocol
35%
Judgment and local capacity
73R/R follicular lymphomaseveral comorbidities, ninety-minute drive to the center
Their reserve, or your escalation plan?
Where does the evidence land?
65%
Facts about the patient
36%
The escalation plan